DE602007013252D1 - Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen - Google Patents

Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen

Info

Publication number
DE602007013252D1
DE602007013252D1 DE602007013252T DE602007013252T DE602007013252D1 DE 602007013252 D1 DE602007013252 D1 DE 602007013252D1 DE 602007013252 T DE602007013252 T DE 602007013252T DE 602007013252 T DE602007013252 T DE 602007013252T DE 602007013252 D1 DE602007013252 D1 DE 602007013252D1
Authority
DE
Germany
Prior art keywords
nucleoside
hydrolases
azyclic
amininhibitors
phosphole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602007013252T
Other languages
English (en)
Inventor
Keith Clinch
Gary Brian Evans
Richard Hubert Furneaux
Peter Michael Kelly
Vern L Schramm
Peter Charles Tyler
Anthony David Woolhouse
Shivali Ashwin Gulab
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IND RES Ltd
Industrial Research Ltd
Albert Einstein College of Medicine
Original Assignee
IND RES Ltd
Industrial Research Ltd
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IND RES Ltd, Industrial Research Ltd, Albert Einstein College of Medicine filed Critical IND RES Ltd
Publication of DE602007013252D1 publication Critical patent/DE602007013252D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
DE602007013252T 2006-09-07 2007-09-07 Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen Active DE602007013252D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84286706P 2006-09-07 2006-09-07
PCT/NZ2007/000261 WO2008030119A1 (en) 2006-09-07 2007-09-07 Acyclic amine inhibitors of nucleoside phosphorylases and hydrolases

Publications (1)

Publication Number Publication Date
DE602007013252D1 true DE602007013252D1 (de) 2011-04-28

Family

ID=39157466

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602007013252T Active DE602007013252D1 (de) 2006-09-07 2007-09-07 Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen

Country Status (20)

Country Link
US (1) US8853224B2 (de)
EP (2) EP2395005A1 (de)
JP (1) JP5388067B2 (de)
KR (1) KR101433621B1 (de)
CN (1) CN101528749B (de)
AT (1) ATE502038T1 (de)
AU (1) AU2007293774C1 (de)
CA (1) CA2662628C (de)
CY (1) CY1111507T1 (de)
DE (1) DE602007013252D1 (de)
DK (1) DK2057165T3 (de)
ES (1) ES2362805T3 (de)
HK (1) HK1131612A1 (de)
HR (1) HRP20110408T1 (de)
NZ (1) NZ575365A (de)
PL (1) PL2057165T3 (de)
PT (1) PT2057165E (de)
RS (1) RS51864B (de)
SI (1) SI2057165T1 (de)
WO (1) WO2008030119A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4682314B2 (ja) 2002-08-21 2011-05-11 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ヌクレオシドホスホリラーゼおよびヌクレオシダーゼの阻害剤
NZ533360A (en) 2004-06-04 2007-02-23 Ind Res Ltd Improved method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
CA2615549A1 (en) 2005-07-27 2007-02-08 Albert Einstein College Of Medicine Of Yeshiva University Transition state structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases
WO2007097643A1 (en) 2006-02-22 2007-08-30 Industrial Research Limited Analogues of coformycin and their use for treating protozoan parasite infections
EP1991230A4 (de) 2006-02-24 2010-12-15 Einstein Coll Med Verfahren zur behandlung von krebs
CA2662626C (en) * 2006-09-07 2016-07-26 Industrial Research Limited Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
NZ577682A (en) 2006-12-22 2012-03-30 Einstein Coll Med Azetidine analogues of nucleosidase and phosphorylase inhibitors
US20090247750A1 (en) * 2008-03-28 2009-10-01 Biocryst Pharmaceuticals, Inc. Process for preparing nucleoside analogs
EP2348854A4 (de) * 2008-09-22 2012-03-14 Einstein Coll Med Verfahren und zusammensetzungen für die behandlung von bakteriellen infektionen durch hemmung des »quorum sensing
DK2454263T3 (en) 2009-07-17 2018-10-01 Albert Einstein College Medicine Inc 3-HYDROXYPYRROLIDE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND - NUCLEOSIDASE
AR077898A1 (es) 2009-08-26 2011-09-28 Nycomed Gmbh Metilpirrolopirimidincarboxamidas
JP6274723B2 (ja) 2009-10-16 2018-02-07 メリンタ セラピューティクス，インコーポレイテッド 抗微生物性化合物および抗微生物性化合物の製造方法および使用方法
KR20190044136A (ko) 2009-10-16 2019-04-29 멜린타 서브시디어리 코프. 항미생물성 화합물 및 이의 제조 방법 및 사용 방법
US9216979B2 (en) 2009-10-16 2015-12-22 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US20130331404A1 (en) 2010-10-15 2013-12-12 Biocryst Pharmaceuticals, Inc. Methods and Compositions for Inhibition of Polymerase
WO2012074912A1 (en) * 2010-11-29 2012-06-07 Albert Einstein College Of Medicine Of Yeshiva University Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase
EP2646410B1 (de) * 2010-11-30 2018-05-16 Connora Technologies, Inc. Neue mittel für aufbereitbare epoxidharze
CN103958514B (zh) * 2011-04-15 2018-07-03 梅琳塔治疗公司 抗微生物化合物及制备和使用所述化合物的方法
WO2012150866A1 (en) * 2011-05-03 2012-11-08 Industrial Research Limited Phosphoribosyltransferase inhibitors and uses thereof
KR101810055B1 (ko) 2011-08-10 2017-12-18 아도시아 하나 이상의 유형의 기저 인슐린의 주사액
CN107583039A (zh) 2012-01-09 2018-01-16 阿道恰公司 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
JP6063571B2 (ja) 2012-08-07 2017-01-18 アルバート アインシュタイン カレッジ オブ メディシン，インコーポレイティド ヘリコバクター・ピロリ感染の治療
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
EP3010340A4 (de) * 2013-06-22 2017-08-02 Nitor Therapeutics Zusammensetzungen und verfahren zur verstärkung einer immunantwort, zur immuntherapieverbesserung und zur erhöhung der potenz von impfstoffen
EP3019503B1 (de) 2013-07-12 2017-09-06 Gilead Sciences, Inc. Polycyclische-carbamoylpyridon-verbindungen und deren verwendung zur behandlung von hiv-infektionen
NO2865735T3 (de) 2013-07-12 2018-07-21
WO2015035426A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compunds and methods of making and using the same
CA2923179A1 (en) 2013-09-09 2015-03-12 Melinta Therapeutics, Inc. Antimicrobial compounds and methods of making and using the same
US10118928B2 (en) 2014-02-12 2018-11-06 Albert Einstein College Of Medicine, Inc. Treatment of H. pylori infections using MTAN inhibitors
JP2018507881A (ja) 2015-03-11 2018-03-22 メリンタ セラピューティクス，インコーポレイテッド 抗微生物化合物ならびにこれらを作製および使用する方法
AU2017229105B2 (en) 2016-03-06 2021-08-12 Biocryst Pharmaceuticals, Inc. Methods and compositions for treatment of Zika virus infection
US10472312B2 (en) * 2016-03-15 2019-11-12 Shionogi & Co., Ltd. Method for producing phenoxyethanol derivative
US11098047B2 (en) 2016-05-06 2021-08-24 BioVersys AG Antimicrobials and methods of making and using same
CN113045484B (zh) * 2019-12-27 2024-01-26 南京药石科技股份有限公司 一种2-氨基-2-(1-甲基-4-哌啶基)丙烷-1-醇的制备方法
CN111320634A (zh) * 2020-04-14 2020-06-23 浙江工业大学 一种乙酰氧取代的吡咯并[2,3-d]嘧啶衍生物的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0920777A (ja) 1995-06-30 1997-01-21 Nippon Paper Ind Co Ltd 新規なプリンヌクレオシド誘導体、その製造方法及びその誘導体を有効成分とする酵素阻害剤
US6379911B2 (en) * 1996-02-23 2002-04-30 Albert Einstein College Of Medicine Of Yeshiva University Enzyme detection/assay method and substrates
US5985848A (en) * 1997-10-14 1999-11-16 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of nucleoside metabolism
US6228741B1 (en) 1998-01-13 2001-05-08 Texas Instruments Incorporated Method for trench isolation of semiconductor devices
ES2625636T3 (es) 1999-04-08 2017-07-20 Victoria Link Limited Proceso para preparar inhibidores del metabolismo de nucleósidos
US6448799B1 (en) * 1999-09-30 2002-09-10 Hitachi Electronics Engineering Co., Ltd. Timing adjustment method and apparatus for semiconductor IC tester
JP2004507534A (ja) * 2000-08-29 2004-03-11 インダストリアル　リサーチ　リミテッド ヌクレオシド代謝阻害剤
US6458799B1 (en) 2000-08-31 2002-10-01 Biocryst Pharmaceuticals, Inc. Deazaguanine analog, preparation thereof and use thereof
JP2002296365A (ja) * 2001-03-29 2002-10-09 Seiko Epson Corp 電子機器、電子制御式機械時計、電子機器の制御方法
TW200306191A (en) * 2002-02-22 2003-11-16 Teijin Ltd Pyrrolopyrimidine derivatives
US7098334B2 (en) * 2002-03-25 2006-08-29 Industrial Research Limited 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases
JP4682314B2 (ja) * 2002-08-21 2011-05-11 アルバート アインシュタイン カレッジ オブ メディシン オブ イエシバ ユニバーシティ ヌクレオシドホスホリラーゼおよびヌクレオシダーゼの阻害剤
GB0301736D0 (en) 2003-01-24 2003-02-26 Xenova Ltd Pharmaceutical compounds
NZ523970A (en) * 2003-02-04 2005-02-25 Ind Res Ltd Process for preparing inhibitors of nucleoside phoshorylases and nucleosidases
NZ533360A (en) 2004-06-04 2007-02-23 Ind Res Ltd Improved method for preparing 3-hydroxy-4-hydroxymethyl-pyrrolidine compounds
WO2006014913A2 (en) 2004-07-27 2006-02-09 Biocryst Pharmaceuticals, Inc. Inhibitors of 5'-methylthioadenosine phosphorylase and 5'methylthioadenosine/s-adenosylhomocysteine nucleosidase
NZ540160A (en) 2005-05-20 2008-03-28 Einstein Coll Med Inhibitors of nucleoside phosphorylases
CA2615549A1 (en) 2005-07-27 2007-02-08 Albert Einstein College Of Medicine Of Yeshiva University Transition state structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases
NZ544187A (en) 2005-12-15 2008-07-31 Ind Res Ltd Deazapurine analogs of 1'-aza-l-nucleosides
RU2008129873A (ru) * 2005-12-23 2010-01-27 Новартис АГ (CH) Конденсированные гетероциклические соединения, полезные в качестве ингибиторов дпп-iv
WO2007097648A1 (en) 2006-02-24 2007-08-30 Industrial Research Limited Methods of treating diseases using inhibitors of nucleoside phosphorylases and nucleosidases
EP1991230A4 (de) 2006-02-24 2010-12-15 Einstein Coll Med Verfahren zur behandlung von krebs
CA2662626C (en) 2006-09-07 2016-07-26 Industrial Research Limited Acyclic amine inhibitors of 5'-methylthioadenosine phosphorylase and nucleosidase
US20100062995A1 (en) 2006-09-26 2010-03-11 Schramm Vern L Transition state structure of human 5'methylthioadenosine phosphorylase
NZ577682A (en) 2006-12-22 2012-03-30 Einstein Coll Med Azetidine analogues of nucleosidase and phosphorylase inhibitors
WO2009082247A1 (en) 2007-12-21 2009-07-02 Industrial Research Limited Process for preparing immucillins having a methylene link
EP2348854A4 (de) 2008-09-22 2012-03-14 Einstein Coll Med Verfahren und zusammensetzungen für die behandlung von bakteriellen infektionen durch hemmung des »quorum sensing
DK2454263T3 (en) 2009-07-17 2018-10-01 Albert Einstein College Medicine Inc 3-HYDROXYPYRROLIDE INHIBITORS OF 5'-METHYLTHIOADENOSINE PHOSPHORYLASE AND - NUCLEOSIDASE

Also Published As

Publication number Publication date
EP2395005A1 (de) 2011-12-14
ES2362805T3 (es) 2011-07-13
EP2057165B1 (de) 2011-03-16
DK2057165T3 (da) 2011-06-27
US20110130412A1 (en) 2011-06-02
SI2057165T1 (sl) 2011-07-29
CN101528749B (zh) 2013-07-31
AU2007293774A1 (en) 2008-03-13
NZ575365A (en) 2012-02-24
US8853224B2 (en) 2014-10-07
KR20090069281A (ko) 2009-06-30
HK1131612A1 (en) 2010-01-29
CN101528749A (zh) 2009-09-09
RS51864B (en) 2012-02-29
EP2057165A4 (de) 2009-09-02
KR101433621B1 (ko) 2014-08-27
WO2008030119A9 (en) 2009-09-24
CY1111507T1 (el) 2015-08-05
PL2057165T3 (pl) 2011-08-31
JP5388067B2 (ja) 2014-01-15
JP2010502696A (ja) 2010-01-28
HRP20110408T1 (hr) 2011-06-30
WO2008030119A1 (en) 2008-03-13
EP2057165A1 (de) 2009-05-13
ATE502038T1 (de) 2011-04-15
CA2662628C (en) 2016-02-09
AU2007293774B2 (en) 2013-07-04
AU2007293774C1 (en) 2014-12-18
CA2662628A1 (en) 2008-03-13
PT2057165E (pt) 2011-05-12

Similar Documents

Publication Publication Date Title
DE602007013252D1 (de) Azyklische amininhibitoren von nukleosidphosphorylasen und hydrolasen
ATE552259T1 (de) Inhibitoren von nukleosidphosphorylasen und - nukleosidasen
CY1123625T1 (el) Συνθεσεις και μεθοδοι για θεραπεια διαταραχων χρησης αλκοολης, πονου και αλλων ασθενειων
CY1116929T1 (el) Παραγωγα πυρρολο[2,3-d]πυριμιδινης ως αναστολεις πρωτεϊνικης κινασης β
LTPA2017009I1 (lt) Brutono tirozinkinazės inhibitoriai
TW200714604A (en) Substituted heterocycles and the uses thereof
DE60336734D1 (de) Sidasen
CY1114617T1 (el) Αμινοτετραϋδροπυρανια ως αναστολεις διπεπτιδυλο πεπτιδασης-iv για την αγωγη ή προληψη διαβητη
MY140291A (en) Sulfoximine-substituted pyrimidines for use as cd and/or vegf inhibitors, the production thereof and their use as drugs
CY1111757T1 (el) Παραγωγα ξανθινης ως εκλεκτικοι αναστολεις ημ74α
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
NO20073790L (no) Kjemiske forbindelser
NO20073788L (no) Kjemiske forbindelser
DK1951729T3 (da) Oxygenbundne pyrimidinderivater
EA200701930A1 (ru) Производные пиримидина для лечения гиперпролиферативных нарушений
DE602007010764D1 (en) Benzamidglucokinaseaktivatoren
CY1111899T1 (el) Καινοφανη παραγωγα πυρρολης με δραστηριοτητα αναστολεα της απακετυλασης της ιστονης
MX2009004625A (es) Derivados de 3-amino-pirazol-4-carboxamida utiles como inhibidores de proteina cinasas.
MA32399B1 (fr) Isoquinoléines et isoquinoléinones 6-substituées.
FR2877667B1 (fr) Derives de 4,7-dioxobenzothiazole-2-carboxamides, leur preparation et leurs applications therapeutiques
UA95260C2 (ru) Производное 4-(3-аминопиразол)пиримидина и его применение для лечения злокачественного новообразования
CY1114807T1 (el) Ενωσεις 2,4-πυριμιδινοδιαμινης για τη θεραπευτικη αντιμετωπιση ή την προληψη αυτοανοσων νοσων
UA107920C2 (en) Substituted pyrimidine for the treatment of diseases such as cancer
UA100390C2 (en) Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
CY1114194T1 (el) Αναστολεις δραστικοτητας ακτ